In IVF-ET cycles—

Once-daily Crinone 8% Provided Pregnancy Rates Comparable to Endometrin^® BID/TID¹

Study design: Results of a prospective, randomized, multicenter trial of 1211 women receiving progesterone for an IVF-ET cycle. ICSI, assisted hatching, and co-culture also were allowed. Starting on the day of oocyte retrieval, patients received Crinone 8% (90 mg QD) or Endometrin (100 mg BID or TID).

Endometrin is a registered trademark of Ferring Pharmaceuticals.

Reference: 1. Doody K, Shamma N, Paulson R, Bayer S, Blake E, Yankov V. Endometrin® for luteal phase support in a randomized, controlled, open-label, prospective IVF clinical trial using a combination of Menopur® and Bravelle®. Fertil Steril. 2007;87(Suppl 2):S24. Abstract P-34.

Important Safety Information

The most common side effects of CRINONE (progesterone gel) 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE 8% is contraindicated in patients with active, or a history of, thrombophlebitis or thromboembolic disorders, patients who have known sensitivity to CRINONE 8%, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs. Should any of the earliest manifestations of thrombotic disorders occur, the drug should be discontinued immediately. No adequate evidence is available to show that progesterone and progestins are effective in preventing miscarriage in women with a history of recurrent spontaneous pregnancy losses. The pretreatment physical exam should include special reference to breast and pelvic organs as well as a Papanicolaou smear. Nonfunctional causes of breakthrough bleeding should be considered, and for undiagnosed vaginal bleeding, diagnostic measures should be undertaken. Special care should be taken with patients who have conditions that may be influenced by fluid retention, those who have a history of psychic depression, and those with diabetes.